-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Buy on Relay Therapeutics, Raises Price Target to $22

Benzinga·04/28/2026 16:10:09
Listen to the news
Goldman Sachs analyst Salveen Richter maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $13 to $22.